Salvadori Nicolas, Fan B., Teeyasoontranon W., Ngo-Giang-Huong Nicole, Cressey Tim, Decker Luc, Jourdain Gonzague, et al. (2019). Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus. Clinical Infectious Diseases, 69 (1), p. 144-146. ISSN 1058-4838.
Titre du document
Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal Tenofovir Disoproxil Fumarate to prevent mother-to-child transmission of hepatitis B virus
Salvadori Nicolas, Fan B., Teeyasoontranon W., Ngo-Giang-Huong Nicole, Cressey Tim, Decker Luc, Jourdain Gonzague, et al.
Source
Clinical Infectious Diseases, 2019,
69 (1), p. 144-146 ISSN 1058-4838
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth.
